Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

BACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline characteristics. Data on treating HCV GT4 with LDV/...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Saudi J Gastroenterol
Egile Nagusiak: Babatin, Mohammed A., AlGhamdi, Abdullah S., Assiri, Abdullah M., AlBiladi, Haziz, AlOthmani, Hammad S., Mogharbel, Mohammed H., Mahallawi, Wedad, Asselah, Tarik, Sanai, Faisal M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Medknow Publications & Media Pvt Ltd 2019
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6373216/
https://ncbi.nlm.nih.gov/pubmed/30117490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sjg.SJG_189_18
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak